Aethlon Medical Announces Second HIV/AIDS Treatment Site

Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has added a second HIV/AIDS clinical study location at the Bhvani Hospital in Bihar, India. Aethlon previously disclosed plans to initiate the “first-in-man” clinical study of a medical device to treat the Human Immunodeficiency Virus (HIV), which causes Acquired Immune Deficiency Syndrome (AIDS). The Aethlon Hemopurifier is a medical device created to provide real-time therapeutic filtration of infectious viruses and immunosuppressive proteins. The Hemopurifier holds promise to extend the lives of AIDS patients by removing HIV strains that cause drug failure and reducing the presence of viral proteins that kill-off immune cells. On June 24th, Aethlon announced that its first HIV/AIDS treatment study had been approved by the Institutional Ethics Committee at Jattinder Gambhir Hospital (J.G. Hospital) in Punjab, India. Clinical studies at both site locations are anticipated to begin in September.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier , a first-in-class medical device designed to treat infectious disease. The Hemopurifier provides real-time therapeutic filtration of infectious viruses and immunosuppressive particles, and is positioned to address the treatment of drug and vaccine resistant viruses. Additionally, the device holds promise in cancer care, as research studies have verified the Hemopurifier is able to capture immunosuppressive particles secreted by tumors. The Hemopurifier is designed to act both as a stand-alone therapeutic, and as an adjunct treatment to enhance clinical benefit of established therapies. Pre-clinical studies conducted by researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier in capturing from circulation the viruses that constitute pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The company is conducting studies to support the use of the Hemopurifier as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon demonstrated the safety of the Hemopurifier in a 24-treatment human study at the Apollo Hospital in Delhi, India, and is currently conducting further human studies at the Fortis Hospital, also located in Delhi. The company has submitted an investigational device exemption (IDE) to the U.S. Food and Drug Administration (FDA) to advance the Hemopurifier as a broad-spectrum treatment countermeasure against category “A” bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier technology is available online at www.aethlonmedical.com.